Breast cancer patients receiving Herceptin treatment should be monitored for heart damage at any age

Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences and the Ted Rogers Centre for Heart Research, University Health Network.
Go to Source